[ad_1]
Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
1.2% of Meihua International Medical Technologies shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 66.6% of Meihua International Medical Technologies shares are owned by insiders. Comparatively, 6.3% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Meihua International Medical Technologies and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Meihua International Medical Technologies | N/A | N/A | N/A |
| NovoCure | -25.93% | -41.48% | -12.74% |
Earnings & Valuation
This table compares Meihua International Medical Technologies and NovoCure”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Meihua International Medical Technologies | $96.91 million | 0.07 | $11.62 million | N/A | N/A |
| NovoCure | $621.71 million | 3.18 | -$207.04 million | ($1.51) | -11.76 |
Meihua International Medical Technologies has higher earnings, but lower revenue than NovoCure.
Risk and Volatility
Meihua International Medical Technologies has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Meihua International Medical Technologies and NovoCure, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Meihua International Medical Technologies | 0 | 0 | 0 | 0 | 0.00 |
| NovoCure | 0 | 2 | 4 | 0 | 2.67 |
NovoCure has a consensus target price of $32.83, suggesting a potential upside of 84.87%. Given NovoCure’s stronger consensus rating and higher possible upside, analysts clearly believe NovoCure is more favorable than Meihua International Medical Technologies.
Summary
NovoCure beats Meihua International Medical Technologies on 7 of the 12 factors compared between the two stocks.
About Meihua International Medical Technologies
Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People’s Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People’s Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for Meihua International Medical Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Meihua International Medical Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link